4166 Stock Overview
Orient Pharma Co., Ltd. engages in the research and development, manufacturing, and sales of drugs in Taiwan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Orient Pharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$23.15 |
| 52 Week High | NT$25.45 |
| 52 Week Low | NT$18.55 |
| Beta | 0.19 |
| 1 Month Change | 15.17% |
| 3 Month Change | 11.30% |
| 1 Year Change | 1.09% |
| 3 Year Change | 32.66% |
| 5 Year Change | 22.49% |
| Change since IPO | -38.57% |
Recent News & Updates
Shareholder Returns
| 4166 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 2.9% | -1.0% | -3.7% |
| 1Y | 1.1% | 10.0% | 24.4% |
Return vs Industry: 4166 underperformed the TW Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: 4166 underperformed the TW Market which returned 24.4% over the past year.
Price Volatility
| 4166 volatility | |
|---|---|
| 4166 Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.3% |
| 10% least volatile stocks in TW Market | 2.0% |
Stable Share Price: 4166 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4166's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | n/a | Nguyen Van Vinh | www.oppharma.com |
Orient Pharma Co., Ltd. engages in the research and development, manufacturing, and sales of drugs in Taiwan and internationally. The company develops anti-psychotics and psychostimulants, as well as drugs for treating Parkinson’s and Alzheimer’s diseases; and products for the treatment of sialorrhea, tuberculosis, and attention deficit hyperactivity disorder. It is also developing drug delivery technologies, such as multi-stages-controlled release technology, trans-dermal patches, oral disintegrating tablets, sustained release technology, and micro granules.
Orient Pharma Co., Ltd. Fundamentals Summary
| 4166 fundamental statistics | |
|---|---|
| Market cap | NT$5.16b |
| Earnings (TTM) | NT$22.29m |
| Revenue (TTM) | NT$889.91m |
231.7x
P/E Ratio5.8x
P/S RatioIs 4166 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4166 income statement (TTM) | |
|---|---|
| Revenue | NT$889.91m |
| Cost of Revenue | NT$421.25m |
| Gross Profit | NT$468.67m |
| Other Expenses | NT$446.38m |
| Earnings | NT$22.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 52.66% |
| Net Profit Margin | 2.50% |
| Debt/Equity Ratio | 29.2% |
How did 4166 perform over the long term?
See historical performance and comparison